CD274 and non-small cell lung carcinoma: Regardless of PD-L1 expression, nivolumab plus ipilimumab with or without chemotherapy provided OS benefit compared with chemotherapy alone in untreated metastatic NSCLC (Hellmann et al., 2019; Paz-Ares et al., 2021).